Table 1. Baseline Patient Demographic and Clinical Characteristics.
| Chemotherapy plus rmhTNF (N = 265) No. (%) | Chemotherapy (N = 264) No. (%) | |
|---|---|---|
| Age (years) | ||
| Median | 54.2 | 55.6 |
| Range | 27-69 | 28-70 |
| Sex | ||
| Male | 170 (64) | 164 (62) |
| Female | 95 (36) | 100 (38) |
| Smoking status | ||
| Current and Former | 140 (53) | 143 (54) |
| Never | 125 (47) | 121 (46) |
| Stage of disease | ||
| IIIB | 175 (66) | 174 (66) |
| IV | 90 (34) | 90 (34) |
| Histological type | ||
| Adenocarcinoma | 125 (47) | 126 (48) |
| Squamous cell carcinoma Large cell carcinoma Others | 140 (53) | 138 (52) |
| ECOG PS | ||
| 0 | 69 (26) | 74 (28) |
| 1 | 196 (74) | 190 (72) |
| Chemotherapy regimen | ||
| Docetaxel + Carboplatin | 241 (91) | 246 (93) |
| Docetaxel + Cisplatin | 24 (9) | 18 (7) |
| Time since diagnosis (weeks) | ||
| Median (Range) | 10.2 (1–79) | 11 (1–146) |
| Prior therapy | ||
| Chemotherapy | 148 (56) | 145 (55) |
| Surgery | 138 (52) | 156 (59) |
| Biologic therapy (monoclonal antibodies, vaccines) | 64 (24) | 66 (25) |
| Radiotherapy | 29 (11) | 24 (9) |
| Follow-up anticancer therapy | N = 260 | N = 260 |
| Any therapy | 150 (58) | 181 (70) |
| Chemotherapy | 116 (45) | 130 (50) |
| Radiotherapy | 15 (6) | 21 (8) |
| Biologic therapy | 44 (17) | 59 (23) |
| Surgery | 8 (3) | 5 (2) |
| Unknown | 27 (10) | 8 (3) |
ECOG PS: Eastern Cooperative Oncology Group Performance Status.